| 9.52 -0.01 (-0.1%) | 12-05 16:00 | |||||||||||||
|
|
| Short term | |
|||
| Mid term | ||||
| Targets | 6-month : | 11.29 |
1-year : | 11.64 |
| Resists | First : | 9.67 |
Second : | 9.97 |
| Pivot price | 9.66 |
|||
| Supports | First : | 9.18 |
Second : | 7.64 |
| MAs | MA(5) : | 9.6 |
MA(20) : | 9.67 |
| MA(100) : | 9.47 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 6.4 |
D(3) : | 19.9 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 11.42 | Low : | 8.71 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HLN ] has closed above bottom band by 19.9%. Bollinger Bands are 34.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.61 - 9.66 | 9.66 - 9.7 |
| Low: | 9.35 - 9.41 | 9.41 - 9.47 |
| Close: | 9.41 - 9.5 | 9.5 - 9.6 |
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Fri, 05 Dec 2025
What Does the Market Think About Haleon PLC? - Benzinga
Fri, 05 Dec 2025
Dodge & Cox Decreases Holdings in Haleon PLC Sponsored ADR $HLN - MarketBeat
Tue, 02 Dec 2025
Haleon PLC Updates on Total Voting Rights and Share Capital - The Globe and Mail
Tue, 02 Dec 2025
Haleon PLC Sponsored ADR (NYSE:HLN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Mon, 01 Dec 2025
Quadrant Capital Group LLC Cuts Position in Haleon PLC Sponsored ADR $HLN - MarketBeat
Fri, 14 Nov 2025
Are Investors Undervaluing Haleon plc (LON:HLN) By 35%? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 4,450 (M) |
| Shares Float | 9,000 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 12.3 (%) |
| Shares Short | 10,250 (K) |
| Shares Short P.Month | 9,040 (K) |
| EPS | 0.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.75 |
| Profit Margin | 13.8 % |
| Operating Margin | 22.2 % |
| Return on Assets (ttm) | 4.6 % |
| Return on Equity (ttm) | 9.3 % |
| Qtrly Rev. Growth | -1.3 % |
| Gross Profit (p.s.) | 1.57 |
| Sales Per Share | 2.47 |
| EBITDA (p.s.) | 0.59 |
| Qtrly Earnings Growth | 34.7 % |
| Operating Cash Flow | 2,490 (M) |
| Levered Free Cash Flow | 1,920 (M) |
| PE Ratio | 21.63 |
| PEG Ratio | 0 |
| Price to Book value | 5.4 |
| Price to Sales | 3.84 |
| Price to Cash Flow | 17.01 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |